Ravi Kane, PhD, MS

Research Program

Discovery and Developmental Therapeutics
Phone Number

404-385-4608
Email Address

ravi.kane@chbe.gatech.edu

Biography

Ravi Kane, PhD, MS, is a professor in the School of Chemical and Biomolecular Engineering and Garry Betty/ V Foundation Chair at the Georgia Institute of Technology. He is also a GRA Eminent Scholar in Cancer Nanotechnology.

Dr. Kane is a member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute.

Education

Dr. Kane received his Master of Science and his PhD in chemical engineering from Massachusetts Institute of Technology.

Titles & Roles

Professor

School of Chemical and Biomolecular Engineering, Georgia Institute of Technology

Research

Dr. Kane's research interests include vaccine design, the development of methods to modulate Wnt signaling and the development of imaging techniques and targeted treatments for cancer.

Publications

Title/Journal	Authors	Publication Date
Facile generation of drug-like conformational antibodies specific for amyloid fibrils. Nature chemical biology	AA Desai, JM Zupancic, H Trzeciakiewicz, JE Gerson, KN DuBois, ME Skinner, LM Sharkey, N McArthur, SP Ferris, NN Bhatt, EK Makowski, MD Smith, H Chen, J Huang, C Jerez, YH Kuo, RS Kane, NM Kanaan, HL Paulson, PM Tessier	04/29/2025
Potent bivalent nanobody constructs that protect against the SARS-CoV-2 XBB variant. Npj viruses	PJ Halfmann, JS Lee, N McArthur, O Gupta, Y Kawaoka, RS Kane	03/13/2025
A modular cell-free protein biosensor platform using split T7 RNA polymerase. Science advances	MA McSweeney, AT Patterson, K Loeffler, R Cuellar Lelo de Larrea, MP McNerney, RS Kane, MP Styczynski	02/21/2025
Multivalent S2 subunit vaccines provide broad protection against Clade 1 sarbecoviruses in female mice. Nature communications	PJ Halfmann, RS Patel, K Loeffler, A Yasuhara, LA Van De Velde, JE Yang, J Chervin, C Troxell, M Huang, N Zheng, ER Wright, PG Thomas, PC Wilson, Y Kawaoka, RS Kane	01/07/2025
Generation of nanobodies with conformational specificity for tau oligomers that recognize tau aggregates from human Alzheimer's disease samples. Biomaterials science	N McArthur, JD Squire, OJ Onyeachonam, NN Bhatt, C Jerez, AL Holberton, PM Tessier, LB Wood, R Kayed, RS Kane	11/19/2024
Single immunization with an influenza hemagglutinin nanoparticle-based vaccine elicits durable protective immunity. Bioengineering & translational medicine	S Chiba, T Maemura, K Loeffler, SJ Frey, C Gu, A Biswas, M Hatta, Y Kawaoka, RS Kane	09/01/2024
A modular cell-free protein biosensor platform using split T7 RNA polymerase. bioRxiv : the preprint server for biology	MA McSweeney, AT Patterson, K Loeffler, RCL de Larrea, MP McNerney, RS Kane, MP Styczynski	07/19/2024
Introduction. Annual review of chemical and biomolecular engineering	MF Doherty, RA Segalman, RS Kane	07/01/2024
Broad protection against clade 1 sarbecoviruses after a single immunization with cocktail spike-protein-nanoparticle vaccine. Nature communications	PJ Halfmann, K Loeffler, A Duffy, M Kuroda, JE Yang, ER Wright, Y Kawaoka, RS Kane	02/12/2024
Development of a pan-tau multivalent nanobody that binds tau aggregation motifs and recognizes pathological tau aggregates. Biotechnology progress	N McArthur, B Kang, FG Rivera Moctezuma, AT Shaikh, K Loeffler, NN Bhatt, M Kidd, JM Zupancic, AA Desai, N Djeddar, A Bryksin, PM Tessier, R Kayed, LB Wood, RS Kane	01/01/2024

Awards

Dr. Kane won the Biotechnology Progress Award for Excellence in Biological Engineering Publication in 2014. Previously, he was elected to AIMBE College of Fellows in 2013. In 2011, Dr. Kane received the Trustees' Outstanding Teacher Award, RPI. In 2004, he was named to the TR 100, a list of the world's top 100 young innovators, by MIT's Technology Review.